IL15 and neoplasm: (90) demonstrated that IL-15 co-expression in iNKT cells confers resistance to tumor-associated macrophage-mediated immunosuppression, significantly enhancing anti-metastatic efficacy—a strategy now informing next-generation CAR-iNKT designs.